MRNA

Moderna
D

MRNA

246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate -2.01Revenue estimate 556.40M
OverviewFinancialsSignalsForecastEarningsCompany

Moderna debt to equity ratio

Moderna's debt to equity ratio is 0.61: total debt of 4.18B USD against shareholders' equity of 6.84B USD.

Today
0.61
Average, 5 years
0.13
Low, 5 years
0.05
High, 5 years
0.61

Debt to equity = total debt ÷ shareholders' equity = 4.18B ÷ 6.84B = 0.61

Debt to equity
Total debt
Shareholders' equity

Total debt over shareholders' equity at each quarter end.

Debt to equity by year and by quarter

Fiscal yearPeriod endingDebt to equityTotal debtShareholders' equity
Today0.614.18B6.84B
FY202531 Dec 20250.221.90B8.65B
FY202431 Dec 20240.07747.00M10.90B
FY202331 Dec 20230.091.24B13.85B
FY202231 Dec 20220.061.20B19.12B
FY202131 Dec 20210.06916.00M14.15B
FY202031 Dec 20200.09237.00M2.56B
FY201931 Dec 20190.11132.36M1.17B
FY201831 Dec 20180.0233.49M1.53B
FY201731 Dec 20170.0315.69M625.30M
FY201631 Dec 20160.0112.50M841.85M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:Market cap,P/S ratio,ROE (return on equity),Current ratio,All ratios

Common questions about Moderna's debt to equity

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.